Madrigal Pharmaceuticals (MDGL) FCF Margin (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly FCF Margin of 5.24% for Q2 2026, up 2735.0% year-over-year from 0.18% in Q2 2025, and up 109.52% quarter-over-quarter from 55.02% in Q1 2026.
Madrigal Pharmaceuticals (MDGL) FCF Margin (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported FCF Margin for 6 consecutive years, with 5.24% the latest figure, recorded in Q2 2026.
- In Q2 2026, FCF Margin rose 2735.0% year-over-year to 5.24%; the TTM figure through Jun 2026 stood at 16.07% (up 4375.0% YoY), while the FY2025 annual figure was 19.83%, up 23389.0% from the prior year.
- FCF Margin advanced to 5.24% in Q2 2026 per MDGL's latest filing, from 55.02% in the prior quarter.
- Across five years, FCF Margin topped out at 27.5% in Q3 2025 and bottomed at 922.78% in Q2 2024.
- Historically, FCF Margin has averaged 142.63% across 3 years, with a median of 55.02% in 2026.
- Annual changes were most pronounced in 2025 — FCF Margin surged 90067 bps — and 2026, when it soared 975 bps.
- Madrigal Pharmaceuticals' FCF Margin stood at 101.32% in 2024, then soared by 59 bps to 41.44% in 2025, then soared by 113 bps to 5.24% in 2026.
- Business Quant data shows MDGL's FCF Margin at 5.24% in Q2 2026, 55.02% in Q1 2026, and 41.44% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 5.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.24% |
| Mar 31, 2026 | -55.02% |
| Dec 31, 2025 | -41.48% |
| Sep 30, 2025 | 27.54% |
| Jun 30, 2025 | -22.11% |
| Mar 31, 2025 | -64.77% |
| Dec 31, 2024 | -102.54% |
| Sep 30, 2024 | -106.95% |
| Jun 30, 2024 | -922.78% |
| Sep 30, 2012 | -28,593.88% |
| Jun 30, 2012 | -19,197.96% |
| Mar 31, 2012 | -10,476.87% |
| Dec 31, 2011 | -9,100.83% |
| Sep 30, 2011 | -717.55% |
| Jun 30, 2011 | -5,776.78% |
| Mar 31, 2011 | -1,124.15% |
| Dec 31, 2010 | -200.92% |
| Sep 30, 2010 | -258.38% |